Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study

Alessandro Pontes-Arruda, Laércia Ferreira Martins, Samya Maria de Lima, Alexandre Marini Isola, Diogo Toledo, Ederlon Rezende, Marcelo Maia, Gisele Brocco Magnan, Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group, Alessandro Pontes-Arruda, Laércia Ferreira Martins, Samya Maria de Lima, Alexandre Marini Isola, Diogo Toledo, Ederlon Rezende, Marcelo Maia, Gisele Brocco Magnan, Investigating Nutritional Therapy with EPA, GLA and Antioxidants Role in Sepsis Treatment (INTERSEPT) Study Group

Abstract

Introduction: Enteral nutrition (EN) with eicosapentaenoic acid (EPA)/γ-linolenic acid (GLA) is recommended for mechanically ventilated patients with severe lung injury. EPA/GLA has anti-inflammatory benefits, as evidenced by its association with reduction in pulmonary inflammation, improvement in oxygenation and improved clinical outcomes in patients with severe forms of acute lung injury. This study was a prospective, multicenter, randomized, double-blinded, controlled trial designed to investigate whether EPA/GLA could have an effective role in the treatment of patients with early sepsis (systemic inflammatory response syndrome with confirmed or presumed infection and without any organ dysfunction) by reducing the progression of the disease to severe sepsis (sepsis associated with at least one organ failure) or septic shock (sepsis associated with hypotension despite adequate fluid resuscitation). Secondary outcomes included the development of individual organ failure, increased ICU and hospital length of stay, need for mechanical ventilation and 28-day all-cause mortality.

Methods: Randomization was concealed, and patients were allocated to receive, for seven days, either an EPA/GLA diet or an isocaloric, isonitrogenous control diet not enhanced with lipids. Patients were continuously tube-fed at a minimum of 75% of basal energy expenditure × 1.3. To evaluate the progression to severe sepsis and/or septic shock, daily screening for individual organ failure was performed. All clinical outcomes were recorded during a 28-day follow-up period.

Results: A total of 115 patients in the early stages of sepsis requiring EN were included, among whom 106 were considered evaluable. Intention-to-treat (ITT) analysis demonstrated that patients fed the EPA/GLA diet developed less severe sepsis and/or septic shock than patients fed the control diet (26.3% versus 50%, respectively; P = 0.0259), with similar results observed for the evaluable patients (26.4% versus 50.9% respectively; P = 0.0217). The ITT analysis demonstrated that patients in the study group developed cardiovascular failure (36.2% versus 21%, respectively; P = 0.0381) and respiratory failure (39.6% versus 24.6%, respectively; P = 0.0362) less often than the control group. Similarly, when considering only the evaluable patients, fewer patients developed cardiovascular failure (20.7% versus 37.7%, respectively; P = 0.03) and respiratory failure (26.4% versus 39.6%, respectively; P = 0.04). The percentage of patients fed the EPA/GLA diet requiring invasive mechanical ventilation was reduced compared with controls (ITT patients: 18.9% versus 33.9%, respectively; P = 0.394; evaluable patients: 17.5% versus 34.5%, respectively; P = 0.295). Patients nourished with the EPA/GLA diet remained in the ICU fewer days than the control population (ITT patients: 21.1 ICU-free days versus 14.7 ICU-free days, respectively; P < 0.0001; evaluable patients: 20.8 ICU-free days versus 14.3 ICU-free days, respectively; P < 0.0001) and fewer days at the hospital (ITT patients: 19.5 hospital-free days versus 10.3 hospital-free days, respectively; P < 0.0001; evaluable patients: 19.1 hospital-free days versus 10.2 hospital-free days, respectively; P < 0.001) (all numbers expressed as means). No significant differences in 28-day all-cause mortality were observed (ITT patients: 26.2% EPA/GLA diet versus 27.6% control diet, respectively; P = 0.72; evaluable: 26.4 EPA/GLA diet versus 30.18 control diet, respectively; P = 0.79).

Conclusions: These data suggest that EPA/GLA may play a beneficial role in the treatment of enterally fed patients in the early stages of sepsis without associated organ dysfunction by contributing to slowing the progression of sepsis-related organ dysfunction, especially with regard to cardiovascular and respiratory dysfunction.

Trial registration: ClinicalTrials.gov: NCT00981877.

Figures

Figure 1
Figure 1
Participant flow diagram. BEE = basal energy expenditure.
Figure 2
Figure 2
Graph showing incidence of severe sepsis and septic shock.
Figure 3
Figure 3
Graph showing the development of individual system failures.
Figure 4
Figure 4
Kaplan-Meier survival curves graphed for 28-day all-cause mortality.

References

    1. Martindale RG, McClave SA, Vanek VW, McCarthy M, Roberts P, Taylor B, Ochoa JB, Napolitano L, Cresci G. American College of Critical Care Medicine; A.S.P.E.N. Board of Directors. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary. Crit Care Med. 2009;37:1757–1761. doi: 10.1097/CCM.0b013e3181a40116.
    1. Heys SD, Walker LG, Smith I, Eremin O. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Ann Surg. 1999;229:467–477. doi: 10.1097/00000658-199904000-00004.
    1. Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med. 2008;34:1980–1990. doi: 10.1007/s00134-008-1213-6.
    1. Pontes-Arruda A. The use of special lipids in the treatment of inflammatory lung disease. Clin Nutr Insight. 2007;33:1–4.
    1. Pinsky MR. Antioxidant therapy for severe sepsis: promise and perspective. Crit Care Med. 2003;31:2397–2698. doi: 10.1097/01.CCM.0000084847.90332.96.
    1. Bulger EM, Maier RV. Lipid mediators in the pathophysiology of critical illness. Crit Care Med. 2000;28(4 Suppl):N27–N36.
    1. Mayer K, Schaefer MB, Seeger W. Fish oil in the critically ill: from experimental to clinical data. Curr Opin Clin Nutr Metab Care. 2006;9:140–148. doi: 10.1097/01.mco.0000214573.75062.0a.
    1. Wanten GJA, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr. 2007;85:1171–1184.
    1. Deckelbaum RJ, Worgall TS, Seo T. n-3 fatty acids and gene expression. Am J Clin Nutr. 2006;83(6 Suppl):1520S–1525S.
    1. Singer P, Shapiro H, Theilla M, Anbar R, Singer J, Cohen J. Anti-inflammatory properties of Ω-3 fatty acids and critical illness: novel mechanisms and an integrative perspective. Intensive Care Med. 2008;34:1580–1592. doi: 10.1007/s00134-008-1142-4.
    1. Willoughby DA, Moore AR, Colville-Nash PR, Gilroy D. Resolution of inflammation. Int J Immunopharmacol. 2000;22:1131–1135. doi: 10.1016/S0192-0561(00)00064-3.
    1. Haslett C. Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. Clin Sci (Lond) 1992;83:639–648.
    1. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–1197. doi: 10.1038/ni1276.
    1. Bannenberg G, Arita M, Serhan CN. Endogenous receptor agonists: resolving inflammation. ScientificWorldJournal. 2007;7:1440–1462.
    1. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN, Van Dyke TE. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol. 2007;179:7021–7029.
    1. Gadek JE, DeMichele SJ, Karlstad MD, Pacht ER, Donahoe M, Albertson TE, Van Hoozen C, Wennberg AK, Nelson JL, Noursalehi M. Effect of enteral feeding with eicosapentaenoic acid, γ-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit Care Med. 1999;27:1409–1420. doi: 10.1097/00003246-199908000-00001.
    1. Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J. Benefit of an enteral diet enriched with eicosapentaenoic acid and γ-linolenic acid in ventilated patients with acute lung injury. Crit Care Med. 2006;34:1033–1038. doi: 10.1097/01.CCM.0000206111.23629.0A. A published erratum appears in Crit Care Med 2006, 34:1861.
    1. Pontes-Arruda A, Aragão AM, Albuquerque JD. The effects of enteral feeding with eicosapentaenoic acid, γ-linolenic acid and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006;34:2325–2333. doi: 10.1097/01.CCM.0000234033.65657.B6.
    1. Pontes-Arruda A, DeMichele SJ, Seth A, Singer P. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. JPEN J Parenter Enteral Nutr. 2008;32:596–605. doi: 10.1177/0148607108324203.
    1. Clinical Practice Guidelines: Critical Care Nutrition.
    1. Trials of War Criminal before the Nuremberg Military Tribunals. Control Council Law. 1949;10(2):181–182.
    1. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–873. doi: 10.1097/01.CCM.0000117317.18092.E4. Published errata appear in Crit Care Med 2004, 32:1448, and Crit Care Med 2004, 32:2169-2170.
    1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307.
    1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–1655. doi: 10.1378/chest.101.6.1644.
    1. Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ. Extended Evaluation of Recombinant Human Activated Protein C United States Investigators. Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest. 2004;125:2206–2216. doi: 10.1378/chest.125.6.2206.
    1. Walker GA. Common Statistical Methods for Clinical Research with SAS Examples. 2. Cary, NC: SAS Institute Inc; 2002.
    1. Shapiro SS, Wilk MB. An analysis of variance test for normality. Biometrika. 1965;52:591–599.
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. doi: 10.2307/2281868.
    1. Peto R, Pike M, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer. 1977;35:1–39. doi: 10.1038/bjc.1977.1.
    1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini J, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson T, Townsend S, Vender JS, Zimmerman JL, Vincent JL. International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327. doi: 10.1097/01.CCM.0000298158.12101.41.
    1. Shapiro NI, Howell MD, Talmor D, Lahey DB, Ngo L, Buras J, Wolfe R, Weiss JW, Lisbon A. Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. Crit Care Med. 2006;34:1025–1032. doi: 10.1097/01.CCM.0000206104.18647.A8.
    1. Nguyen HB, Corbett SW, Steele R, Banta J, Clark RT, Hayes SR, Edwards J, Cho TW, Wittlake WA. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med. 2007;35:1105–1112. doi: 10.1097/01.CCM.0000259463.33848.3D.
    1. de Alaniz MJ, Marra CA. Glucocorticoid and mineralocorticoid hormones depress liver Δ 5 desaturase activity through different mechanisms. Lipids. 1992;27:599–604. doi: 10.1007/BF02536117.
    1. Mills DE, Huang YS, Narce M, Poisson JP. Psychosocial stress, catecholamines, and essential fatty acid metabolism in rats. Proc Soc Exp Biol Med. 1994;205:56–61.
    1. Palombo JD, DeMichele SJ, Boyce PJ, Noursalehi M, Forse RA, Bistrian BR. Metabolism of dietary α-linolenic acid vs. eicosapentaenoic acid in rat immune cell phospholipids during endotoxemia. Lipids. 1998;33:1099–1105. doi: 10.1007/s11745-998-0311-x.
    1. Fan YY, Chapkin RS. Importance of dietary γ-linolenic acid in human health and nutrition. J Nutr. 1998;128:1411–1414.
    1. Karlstad MD, DeMichele SJ, Leathem WD, Peterson MB. Effect of intravenous lipid emulsions enriched with γ-linolenic acid on plasma n-6 fatty acids and prostaglandin biosynthesis after burn and endotoxin injury in rats. Crit Care Med. 1993;21:1740–1749. doi: 10.1097/00003246-199311000-00025.
    1. Johnson MM, Swan DD, Surette ME, Stegner J, Chilton T, Fonteh AN, Chilton HF. Dietary supplementation with γ-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr. 1997;127:1435–1444.
    1. Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I. The cost of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med. 2003;29:1464–1471. doi: 10.1007/s00134-003-1877-x.
    1. Sogayar AM, Machado FR, Rea-Neto A, Dornas A, Grion CM, Lobo SM, Tura BR, Silva CL, Cal RG, Beer I, Michels V, Safi J, Kayath M, Silva E. Costs Study Group-Latin American Sepsis Institute. A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics. 2008;26:425–434. doi: 10.2165/00019053-200826050-00006.
    1. EDEN-Omega NHLBI ARDS Network. Prospective, Randomized, Multi-Center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) and Prospective, Randomized, Blinded, Placebo-Controlled, Multi-Center Trial of Ω-3 Fatty Acid, γ-Linolenic Acid, and Anti-Oxidant Supplementation in the Management of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)
    1. Palombo JD, DeMichele SJ, Lydon E, Bistrian BR. Cyclic vs continuous enteral feeding with Ω-3 and γ-linolenic fatty acids: effects on modulation of phospholipid fatty acids in rat lung and liver immune cells. JPEN J Parenter Enteral Nutr. 1997;21:123–132. doi: 10.1177/0148607197021003123.
    1. Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, Seeger W, Grimminger F. Parenteral nutrition with fish oil modulates cytokines response in patients with sepsis. Am J Respir Crit Care Med. 2003;167:1321–1328. doi: 10.1164/rccm.200207-674OC.
    1. Heller AR, Rossler S, Litz RJ, Stehr SN, Heller SC, Koch R, Koch T. Ω-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med. 2006;34:972–979. doi: 10.1097/01.CCM.0000206309.83570.45.
    1. Barbosa VM, Miles EA, Calhau C, Lafuente E, Calder PC. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial. Crit Care. 2010;14:R5. doi: 10.1186/cc8844.
    1. Silva E, de Almeida Pedro M, Beltrami Sogayar AC, Mohovic T, de Oliveira Silva CL, Janiszewski M, Rodrigues Cal RG, Fernandes de Sousa É, Abe TP, de Andrade J, Dias de Matos J, Rezende E, Assunção M, Avezum Á, Rocha PCS, Faissol Janot de Matos G, Moreira Bento A, Danielli Corrêa A, Bastos Vieira PC, Knobel E. Brazilian Sepsis Epidemiological Study. Brazilian Sepsis Epidemiological Study (BASES study) Crit Care. 2004;8:R251–R260. doi: 10.1186/cc2892.
    1. Pontes-Arruda A, Martins L, Lima S, Isola AM, Toledo D, Rezende E, Maia M, Magnan G. the INTERSEPT Study Group. Glycemic effects of a high-lipid enteral feeding with EPA, GLA (EPA/GLA) compared to a standard ICU diet in patients with sepsis without organ failures: a prospective, randomized, double-blinded and multicenter trial (INTERSEPT Study) Clin Nutr Suppl. 2010;5:PP013.
    1. Pontes-Arruda A, Martins L, Lima S, Isola AM, Toledo D, Rezende E, Maia M, Magnan G. the INTERSEPT Study Group. Enteral feeding with EPA, GLA (EPA/GLA) in patients with early sepsis without organ dysfunctions: a prospective, randomized, double-blinded multicenter trial (INTERSEPT Study) Clin Nutr Suppl. 2010;5:PP012.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa